Loading patent…
AssigneeDomantis Limited
InventorsSteven Grant, Haiqun Liu, Kevin Moulder
Estimating the term…
The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
A method of antagonizing an activity of CD40 or CD40L in an individual having an autoimmune disease, comprising administering to said individual, a polypeptide comprising a single immunoglobulin variable domain, wherein said single immunoglobulin variable domain specifically binds CD40L independently of an additional antibody VH or VL domain and antagonizes an activity of CD40L and/or antagonizes an activity of CD40 mediated by an interaction between CD40 and CD40L, wherein said single immunoglobulin variable domain consists of an amino acid sequence which is 85% identical to a sequence selected from the group consisting of SEQ ID NOS:
A method of antagonizing an activity of CD40 or CD40L in an individual having a disease or disorder selected from the group consisting of allograft rejection, xenograft transplant rejection, and graft vs. host disease, comprising administering to said individual a polypeptide comprising a single immunoglobulin variable domain, wherein said single immunoglobulin variable domain specifically binds CD40L independently of an additional antibody VH or VL domain and antagonizes the activity of CD40L and/or antagonizes an activity of CD40 mediated by an interaction between CD40 and CD40L, wherein said single immunoglobulin variable domain consists of an amino acid sequence which is 85% identical to a sequence selected from the group consisting of SEQ ID NOS:
Dependencies are inferred from the claim text.